A PI3K p110β-Rac signalling loop mediates Pten-loss-induced perturbation of haematopoiesis and leukaemogenesis

Nature Communications

Volumn 6, Issue , 2015, Pages

  Yuzugullu, Haluk ^a,b   Baitsch, Lukas ^a,b   Von, Thanh ^a,b   Steiner, Allison ^a   Tong, Haoxuan ^a,b   Ni, Jing ^a,b   Clayton, Linda K ^a   Bronson, Roderick ^b   Roberts, Thomas M ^a,b   Gritsman, Kira ^a,b,c   Zhao, Jean J ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRE RECOMBINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P110; PROTEIN P110 BETA; RAC PROTEIN; UNCLASSIFIED DRUG; 1-PHOSPHATIDYLINOSITOL 3-KINASE P110 SUBUNIT, MOUSE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PTEN PROTEIN, MOUSE;

BLOOD SYSTEM DISORDER; CELLS AND CELL COMPONENTS; DISEASE TREATMENT; GENE EXPRESSION; GENETIC ANALYSIS; INHIBITION; METABOLISM; RODENT; TUMOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; EXTRAMEDULLARY HEMATOPOIESIS; FEMALE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; LEUKEMIA; LEUKEMOGENESIS; MOUSE; NONHUMAN; POSITIVE FEEDBACK; PROTEIN DEPLETION; ANIMAL; BONE MARROW; CARCINOGENESIS; CHEMOTAXIS; FLOW CYTOMETRY; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MYELOPROLIFERATIVE DISORDER; WESTERN BLOTTING;

MUS;

ANIMALS; BLOTTING, WESTERN; BONE MARROW; CARCINOGENESIS; CHEMOTAXIS; CLASS I PHOSPHATIDYLINOSITOL 3-KINASES; FLOW CYTOMETRY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; IMMUNOHISTOCHEMISTRY; LEUKEMIA; MICE; MYELOPROLIFERATIVE DISORDERS; PTEN PHOSPHOHYDROLASE; RAC GTP-BINDING PROTEINS;

EID: 84943739934     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms9501     Document Type: Article

References (56)

1. Martelli, A. M. et al. Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia 20, 911-928 (2006).
2. Peng, C. et al. PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice. Blood 115, 626-635 (2010).
3. Gutierrez, A. et al. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood 114, 647-650 (2009).
4. Dahia, P. L. et al. PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies. Hum. Mol. Genet. 8, 185-193 (1999).
5. Patel, J. P. et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N. Engl. J. Med. 366, 1079-1089 (2012).
6. Li, Y. et al. Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway. Blood 121, 499-509 (2013).
7. Noguera, N. I. et al. Nucleophosmin/B26 regulates PTEN through interaction with HAUSP in acute myeloid leukemia. Leukemia 27, 1037-1043 (2013).
8. Yang, J. et al. A reappraisal by quantitative flow cytometry analysis of PTEN expression in acute leukemia. Leukemia 21, 2072-2074 (2007).
9. Xu, Q., Simpson, S. E., Scialla, T. J., Bagg, A. & Carroll, M. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 102, 972-980 (2003).
10. Yilmaz, O. H. et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441, 475-482 (2006).
11. Zhang, J. et al. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 441, 518-522 (2006).
12. Tang, P. et al. Differential roles of Kras and Pten in murine leukemogenesis. Leukemia 27, 1210-1214 (2013).
13. Vardiman, J. W. et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114, 937-951 (2009).
14. Thorpe, L. M., Yuzugullu, H. & Zhao, J. J. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat. Rev. Cancer 15, 7-24 (2014).
15. Utermark, T. et al. The p110alpha and p110beta isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis. Genes Dev. 26, 1573-1586 (2012).
16. Castellano, E. et al. Requirement for interaction of PI3-kinase p110alpha with RAS in lung tumor maintenance. Cancer Cell 24, 617-630 (2013).
17. Gritsman, K. et al. Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110alpha. J. Clin. Invest. 124, 1794-1809 (2014).
18. Ciraolo, E. et al. Phosphoinositide 3-kinase p110beta activity: key role in metabolism and mammary gland cancer but not development. Sci. Signal. 1, ra3 (2008).
19. Guillermet-Guibert, J. et al. The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. Proc. Natl Acad. Sci. USA 105, 8292-8297 (2008).
20. Jia, S. et al. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 454, 776-779 (2008).
21. Fritsch, R. et al. RAS and RHO families of GTPases directly regulate distinct phosphoinositide 3-kinase isoforms. Cell 153, 1050-1063 (2013).
22. Ni, J. et al. Functional characterization of an isoform-selective inhibitor of PI3K-p110beta as a potential anticancer agent. Cancer Discov. 2, 425-433 (2012).
23. Wee, S. et al. PTEN-deficient cancers depend on PIK3CB. Proc. Natl Acad. Sci. USA 105, 13057-13062 (2008).
24. Furman, R. R. et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 370, 997-1007 (2014).
25. Zhao, J. J. et al. The p110alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation. Proc. Natl Acad. Sci. USA 103, 16296-16300 (2006).
26. Jou, S. T. et al. Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex. Mol. Cell. Biol. 22, 8580-8591 (2002).
27. Kuhn, R., Schwenk, F., Aguet, M. & Rajewsky, K. Inducible gene targeting in mice. Science 269, 1427-1429 (1995).
28. Subramaniam, P. S. et al. Targeting nonclassical oncogenes for therapy in T-ALL. Cancer Cell 21, 459-472 (2012).
29. Hagenbeek, T. J. & Spits, H. T-cell lymphomas in T-cell-specific Pten-deficient mice originate in the thymus. Leukemia 22, 608-619 (2008).
30. Hagenbeek, T. J. et al. The loss of PTEN allows TCR alphabeta lineage thymocytes to bypass IL-7 and Pre-TCR-mediated signaling. J. Exp. Med. 200, 883-894 (2004).
31. Tesio, M. et al. Pten loss in the bone marrow leads to G-CSF-mediated HSC mobilization. J. Exp. Med. 210, 2337-2349 (2013).
32. Juric, D. et al. Phase I study of BYL719, an alpha-specific PI3K inhibitor, in patients with PIK3CA mutant advanced solid tumors: preliminary efficacy and safety in patients with PIK3CA mutant ER-positive (ER) metastatic breast cancer (MBC). Cancer Res. 72, P6-10-07 (2012).
33. Lannutti, B. J. et al. CAL-101, a p110delta selective phosphatidylinositol-3- kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 117, 591-594 (2011).
34. Bruce, I. et al. Development of isoform selective PI3-kinase inhibitors as pharmacological tools for elucidating the PI3K pathway. Bioorg. Med. Chem. Lett. 22, 5445-5450 (2012).
35. Sujobert, P. et al. Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood 106, 1063-1066 (2005).
36. Camps, M. et al. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat. Med. 11, 936-943 (2005).
37. Wang, Q. et al. Spatially distinct roles of class Ia PI3K isoforms in the development and maintenance of PTEN hamartoma tumor syndrome. Genes Dev. 27, 1568-1580 (2013).
38. Ali, K. et al. Essential role for the p110delta phosphoinositide 3-kinase in the allergic response. Nature 431, 1007-1011 (2004).
39. Kang, J. H. et al. Phosphorylation of Rho-associated kinase (Rho-kinase/ ROCK/ROK) substrates by protein kinases A and C. Biochimie 89, 39-47 (2007).
40. Denley, A., Kang, S., Karst, U. & Vogt, P. K. Oncogenic signaling of class I PI3K isoforms. Oncogene 27, 2561-2574 (2008).
41. Klarlund, J. K. et al. Signaling by phosphoinositide-3,4,5-trisphosphate through proteins containing pleckstrin and Sec7 homology domains. Science 275, 1927-1930 (1997).
42. Welch, H. C. et al. P-Rex1, a PtdIns(3,4,5)P3- and Gbetagamma-regulated guanine-nucleotide exchange factor for Rac. Cell 108, 809-821 (2002).
43. Cancelas, J. A. et al. Rac GTPases differentially integrate signals regulating hematopoietic stem cell localization. Nat. Med. 11, 886-891 (2005).
44. Gu, Y. et al. Hematopoietic cell regulation by Rac1 and Rac2 guanosine triphosphatases. Science 302, 445-449 (2003).
45. Gao, Y., Dickerson, J. B., Guo, F., Zheng, J. & Zheng, Y. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc. Natl Acad. Sci. USA 101, 7618-7623 (2004).
46. Thomas, E. K. et al. Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease. Cancer Cell 12, 467-478 (2007).
47. Schwartz, S. et al. Feedback suppression of PI3Kalpha signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kbeta. Cancer Cell 27, 109-122 (2015).
48. Berenjeno, I. M. et al. Both p110alpha and p110beta isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor. Biochem. J. 442, 151-159 (2012).
49. Weiner, O. D. et al. A PtdInsP(3)- and Rho GTPase-mediated positive feedback loop regulates neutrophil polarity. Nat. Cell Biol. 4, 509-513 (2002).
50. Shirsat, N. V., Pignolo, R. J., Kreider, B. L. & Rovera, G. A member of the ras gene superfamily is expressed specifically in T, B and myeloid hemopoietic cells. Oncogene 5, 769-772 (1990).
51. Yang, F. C. et al. Rac and Cdc42 GTPases control hematopoietic stem cell shape, adhesion, migration, and mobilization. Proc. Natl Acad. Sci. USA 98, 5614-5618 (2001).
52. Mizukawa, B. et al. Inhibition of Rac GTPase signaling and downstream prosurvival Bcl-2 proteins as combination targeted therapy in MLL-AF9 leukemia. Blood 118, 5235-5245 (2011).
53. Kalaitzidis, D. et al. mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis. Cell Stem Cell 11, 429-439 (2012).
54. Magee, J. A. et al. Temporal changes in PTEN and mTORC2 regulation of hematopoietic stem cell self-renewal and leukemia suppression. Cell Stem Cell 11, 415-428 (2012).
55. Saci, A., Cantley, L. C. & Carpenter, C. L. Rac1 regulates the activity of mTORC1 and mTORC2 and controls cellular size. Mol. Cell. 42, 50-61 (2011).
56. Kalaitzidis, D. & Neel, B. G. Flow-cytometric phosphoprotein analysis reveals agonist and temporal differences in responses of murine hematopoietic stem/progenitor cells. PLoS ONE 3, e3776 (2008).